Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 8Gynecologic 3Tumor-Agnostic 2Head & Neck 2Genitourinary 1Breast 1

Conditions

Neoplasms 54Neoplasm Metastasis 22Adenocarcinoma 13Neoplasms, Unknown Primary 9Carcinoma 2

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Gemcitabine × Tumor-Agnostic × Clear all
NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

NCT00126269 2006-09-08

Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Unknown
192 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡